shutterstock_1155148969_atmosphere1
Atmosphere1 / Shutterstock.com
15 June 2023AmericasMuireann Bolger

MSD wins patent extension feud over post-surgery drug

The three-year dispute revolved around proposed generic versions of a drug used to offset the effects of muscle relaxants | Pharma giant can retain patent until January 2026.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Generics
8 February 2022   AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Big Pharma
21 May 2020   The English High Court has finalised the terms of a trademark injunction against US pharmaceutical company Merck, Sharp and Dohme (MSD), in favour of German rival Merck KGaA.

More on this story

Generics
8 February 2022   AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Big Pharma
21 May 2020   The English High Court has finalised the terms of a trademark injunction against US pharmaceutical company Merck, Sharp and Dohme (MSD), in favour of German rival Merck KGaA.

More on this story

Generics
8 February 2022   AstraZeneca and Merck, Sharp & Dohme have filed a pair of lawsuits against MSN and Sandoz, claiming their planned generic versions of its leukaemia treatment Calquence infringe six patents.
Big Pharma
21 May 2020   The English High Court has finalised the terms of a trademark injunction against US pharmaceutical company Merck, Sharp and Dohme (MSD), in favour of German rival Merck KGaA.